Objective To investigate the effect of rosuvastatin on myocardial function andNT-pro-BNP of rats with diabe-tes. Methods Wistar rats diabetes models were established by high sucrose-fat diet and streptozocin. Diabetes rats were con-tinued to high sucrose-fat diet for two month, and randomly divided into two groups: control group (rats undergoingnormal saline intragastric administration per day), rosuvastatin group (rats undergoing 20mg/kg rosuvastatin intragastric administration per day). The echocardiography, which including LVEDD, LWPWT and EF, were detected at 0, 1 and 2 month after diabetes mod-els establishment. The fasting glucose, triglyceride, total cholesterol and NT-pro-BNP were determined at the end of the exper-iment. The weight of heart and body were weighed and the ratio of heart weight and body weight were calculated. Results At the end of the experiment, LVEDD and LWPWTin rosuvastatin group were lower than those in control group, and EF in rosuvastatin group were higher than those in control group; The fasting glucose levels showed no significant difference, and the triglyceride, total cholesterol and NT-pro-BNP in rosuvastatin group were significantly lower than those in control group; the ratios of heart weight and body weight were significantly lower in rosuvastatin group than that in the control group. Conclusion Rosuvastatin could improve the dyslipidemia, decrease NT-pro-BNP level, and alleviate the myocardial dysfunction and injury of rats with diabetes.%目的:观察瑞舒伐他汀对糖尿病大鼠心肌功能和NT-pro-BNP的影响.方法:利用高糖高脂饲料喂养2个月和链脲佐菌素制备Wistar大鼠糖尿病模型,造模成功后继续原饲料喂养并随机分为对照组和瑞舒伐他汀组.对照组每日予生理盐水灌胃,瑞舒伐他汀组每日予瑞舒伐他汀(20mg/kg)灌胃,持续2个月.观察心脏超声指标左室舒张末期内径(LVEDD)、左室后壁厚度(LWPWT)和左室射血分数(EF)的变化;检测两组大鼠实验末血糖情况,血脂指标甘油三酯(TG)、总胆固醇(TC)和心功能指标N末端脑钠肽前体(NT-pro-BNP);计算心脏重量/体重比.结果:瑞舒伐他汀组大鼠实验末的LVEDD和LWPWT指标低于对照组,EF指标高于对照组差异有统计学意义;实验末两组大鼠空腹血糖相比无明显差异;TG、TC和NT-pro-BNP水平明显低于对照组,瑞舒伐他汀组大鼠实验末心脏重量/体重比显著低于对照组.结论:瑞舒伐他汀能改善脂代谢紊乱,降低NT-pro-BNP水平,减轻糖尿病大鼠心肌功能障碍和损伤.
展开▼
